This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Doxil and Gemcitabine in Recurrent Ovarian Cancer

This study has been terminated.
Ortho Biotech, Inc.
Information provided by:
Women and Infants Hospital of Rhode Island Identifier:
First received: April 6, 2006
Last updated: January 9, 2015
Last verified: January 2015
Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.

Condition Intervention Phase
Ovarian Carcinoma Drug: liposomal doxorubicin and gemcitabine Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer

Resource links provided by NLM:

Further study details as provided by Women and Infants Hospital of Rhode Island:

Primary Outcome Measures:
  • rate of hand-foot syndrome

Secondary Outcome Measures:
  • objective response rate

Estimated Enrollment: 24
Study Start Date: April 2006
Study Completion Date: May 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Detailed Description:
This study will evaluate the toxicities of Doxil and Gemcitabine given on an every two week basis. Our hypothesis is that toxicity will be less than that with standard dosing without any negative effect on survival. Patients will also be evaluated with CT scans every 3 months. Toxicity will be assessed with every cycle of treatment. Treatment will continue until toxicity or signs of progression.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • recurrent platinum resistant ovarian cancer
  • measurable disease

Exclusion Criteria:

  • prior treatment with Doxil or Gemzar
  • life expectancy <3months
  • cardiac ejection fraction <50%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00312650

United States, Rhode Island
Women and Infants' Hospital
Providence, Rhode Island, United States, 02905
Sponsors and Collaborators
Women and Infants Hospital of Rhode Island
Ortho Biotech, Inc.
Principal Investigator: Paul A DiSilvestro, MD Program in Women's Oncology
  More Information Identifier: NCT00312650     History of Changes
Other Study ID Numbers: 05-0120
Study First Received: April 6, 2006
Last Updated: January 9, 2015

Keywords provided by Women and Infants Hospital of Rhode Island:
ovarian cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Liposomal doxorubicin
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on June 23, 2017